Company intelligence / Profile preview
Cellatoz Therapeutics, Inc.
Seongnam-si, Gyeonggi-do, South Koreacellatozrx.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
The company has initiated a Phase 1 clinical trial in South Korea for CLZ‑2002, a Schwann-cell-based regenerative therapy targeting Charcot-Marie-Tooth disease. Preclinical studies have demonstrated safety and efficacy in animal models. Additional programs are in preclinical or discovery stages targeting musculoskeletal disorders and oncology.[6][8]
- Therapeutic areas
- RheumatologyEndocrinologyOtherOncologyNeurology
- Modalities
- Cell therapyMesenchymal stem cell therapyNK cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Ewha Womans University Medical Center"[1]
Beyond the preview
Go deeper on Cellatoz Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellatoz Therapeutics, Inc..